Overview

A Study to Compare Neostigmine vs Sugammadex in Length of PACU Stay in Patients Undergoing Sleeve Gastrectomy Surgery

Status:
Terminated
Trial end date:
2018-11-08
Target enrollment:
Participant gender:
Summary
The investigators will track bariatric patients who received sugammadex versus neostigmine in the post anesthesia care unit until discharge and assess their length of stay and possible nausea / vomiting / hypoxia episodes.
Phase:
Phase 4
Details
Lead Sponsor:
Adam Thaler
Virtua Health, Inc.
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Neostigmine